Skip to main content

Animations

MJFF Publications

2631 - 2640 of 8571 Results
Title
Year
  • Year
  • 2019
  • 2019
  • 2023
  • 2019
  • 2022
  • 2014
  • 2023
  • 2023
  • 2019
  • 2014
  • Summary Details
    RESTRICTED
    Title: Targeting the Dopaminergic System in Autoimmunity
    Journal Name: Journal of Neuroimmune Pharmacology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/s11481-019-09834-5
    Best OA location URL:
    Citation Count: 53
  • Summary Details
    RESTRICTED
    Title: Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2018.11.016
    Best OA location URL:
    Citation Count: 16
  • Summary Details
    RESTRICTED
    Title: Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy?
    Journal Name: Frontiers in Molecular Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnmol.2023.1197853
    Citation Count: 5
  • Summary Details
    RESTRICTED
    Title: Small Molecules to Improve ER Proteostasis in Disease
    Journal Name: Trends in Pharmacological Sciences
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: publisher-specific-oa, publisher-specific-oa
    DOI - Digital Object Identifier: 10.1016/j.tips.2019.07.003
    Citation Count: 63
  • Summary Details
    RESTRICTED
    Title: Clinical neurophysiology of Parkinson’s disease and parkinsonism
    Journal Name: Clinical Neurophysiology Practice
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.cnp.2022.06.002
    Citation Count: 33
  • Summary Details
    RESTRICTED
    Title: Accelerating Drug Development for the Field: Building Clinical Trial Recruitment Infrastructure in Parkinson’s
    Journal Name:
    Publisher:
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.14524/cr-13-00066r1.1
    Best OA location URL:
    Citation Count: 1
  • Summary Details
    RESTRICTED
    Title: Addition to “Nanostars Carrying Multifunctional Neurotrophic Dendrimers Protect Neurons in Preclinical In Vitro Models of Neurodegenerative Disorders”
    Journal Name: ACS Applied Materials & Interfaces
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1021/acsami.3c02300
    Citation Count: 0
  • Summary Details
    RESTRICTED
    Title: Novel therapeutic approaches to target neurodegeneration
    Journal Name: British Journal of Pharmacology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1111/bph.16078
    Citation Count: 7
  • Summary Details
    RESTRICTED
    Title: Huntington disease: A quarter century of progress since the gene discovery
    Journal Name: Journal of the Neurological Sciences
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.jns.2018.09.022
    Best OA location URL:
    Citation Count: 59
  • Summary Details
    RESTRICTED
    Title: REM Sleep Behavior and Motor Findings in Parkinson's Disease: A Cross-sectional Analysis.
    Journal Name:
    Publisher:
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.7916/d84b2zdf
    Best OA location URL:
    Citation Count: 4
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.